What is BIO-PREGABALIN used for?

Although pregabalin is sometimes prescribed for people withbipolar disorder, there is no evidence showing that it is effective. There is no evidence and significant risk in using pregabalin forsciaticaandlow back pain. Evidence of benefit inalcohol withdrawalas well as withdrawal from certain other drugs is limited as of 2016. There is no evidence for its use in the prevention ofmigrainesand gabapentin has also been found not to be useful. A 2025 review found possible benefits to sleep quality i

What are the side effects of BIO-PREGABALIN?

In a systematic review analysing data from 5 cohort studies having 1,085,488 patients, use of gabapentinoids (pregabalin and gabapentin) was associated with an increased risks of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids. Exposure to pregabalin is associated with weight gain,

Does BIO-PREGABALIN interact with other medications?

Few pharmacokinetic drug interactions have been demonstratedin vivo. However, the manufacturer notes potential pharmacological interactions withopioids,benzodiazepines,barbiturates,ethanol(alcohol), and other central nervous system depressants. Concurrent use ofACE inhibitorsand pregabalin may increase the risk ofangioedema. Pregabalin may also enhance the fluid-retaining effects of certain antidiabetic agents, such asthiazolidinediones. Pregabalin may independently increase the risk ofangioedem

Can BIO-PREGABALIN be used during pregnancy?

It is unclear if it is safe for use in pregnancy with some studies showing potential harm.

What ATC class does BIO-PREGABALIN belong to?

BIO-PREGABALIN: ATC N02BF02. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

BIO-PREGABALIN

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

USDailyMed:Pregabalin AU:D GabapentinoidAnticonvulsantGABA analogue N02BF02(WHO)QN02BF02(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyNZ: Rx-onlyUK:Class CUS:Schedule VEU:Rx-onlySE: Förteckning VIn general: Prescription only SE: Förteckning VIn general: Prescription only (3S)-3-(aminomethyl)-5-methylhexanoic acid 148553-50-8Y 5486971 DB00230Y 4589156Y 55JG375S6M D02716Y CHEBI:64356Y ChEMBL1059Y DTXSID1045950 Interactive image CC(C)CC(CC(=O)O)CN InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1YKey:AYXYPKUFHZROOJ-ZETCQYMHSA-NY Pregabalin, sold under the brand namesAxalidandLyricaamong others, is ananticonvulsant,analgesic, andanxiolyticamino acid medication used to treatepilepsy,neuropathic pain,fibromyalgia,restless legs syndrome,opioid withdrawal,generalized anxiety disorder(GAD), andpostherpetic neuralgia(a type of nerve damage that can result fromshingles).Pregabalin also hasantiallodynicproperties.Its use in epilepsy is as an add-on therapy forpartial seizures.When used before surgery, it reduces pain but results in greater sedation and visual disturbances.It is takenby mouth. Common side effects can includeheadache,dizziness,sleepiness,euphoria,confusion, trouble with memory,poor coordination,dry mouth, problems with vision, andweight gain.Serious side effects may includeangioedema, kidney damage, and seizures. As with all other drugs approved by theFDAfor treating epilepsy, the pregabalin labeling warns of an increasedsuiciderisk when combined with other drugs.When pregabalin is taken at high doses over a long period of time, addiction may occur, but if taken atusual dosesthe risk is low.Use during pregnancy or breastfeeding is of unclear safety. It is agabapentinoidmedication which is a class of drugs within thederivativesofγ-aminobutyric acid(GABA analogues), aninhibitory neurotransmitter.Although pregabalin is inactive atGABA receptorsand GABAsynapses, it acts by binding specifically to the α2δ-1 protein that was first described as an auxiliary subunit ofvoltage-gatedcalcium channels. Pregabalin was approved for medical use in the United States in 2004.In the US, pregabalin is aSchedule Vcontrolled substance under theControlled Substances Act of 1970,which means that the drug has low abuse potential compared to substances in Schedules I–IV, however, there is still a potential for misuse.It is available as ageneric medication.In 2023, it was the 78th most commonly prescribed medication in the United States, with more than 8million prescriptions.

BIO-PREGABALIN

User Reviews